Table 1.

Demographics, risk factors, opening pressure and treatment of patients with idiopathic intracranial hypertension with BMI<40 and BMI≥40

	BMI <40 (n=256)		BMI ≥40 (n=158)
Demographics/risk factors	N or median	% or range	N or median	% or range	pValue
Age, y	29.5	[13–62]	28	[13–59]	0.37
Gender [M/F]	15/241	[5.9%/94.1%]	16/142	[10.1%/89.9%]	0.10
Race					0.10
Black	104	[40.6%]	77	[48.7%]
Non-black	152	[59.4%]	81	[51.3%]
Contributing medications*	21	[8.2%]	13	[8.2%]	0.99
Sleep Apnea	13	[5.1%]	26	[16.5%]	<0.001
Anemia	14	[5.5%]	13	[8.2%]	0.26
Endocrine disorder	22	[8.6%]	29	[18.4%]	0.003
Hypertension	35	[13.7%]	40	[25.3%]	0.003
Symptoms
Headache	231	[90.2%]	138	[87.3%]	0.36
Pulsatile tinnitus	104	[40.6%]	58	[36.7%]	0.43
Diplopia	52	[20.3%]	27	[17.1%]	0.42
Transient visual obscurations	97	[37.9%]	66	[41.8%]	0.43
None	2	[0.8%]	6	[3.8%]	0.06
Pre-diagnosis duration of symptoms (wk, n=369)	5.5	[0–500]	5.0	[0–250]	0.35
Follow-up duration (wk, n=376)	23.5	[0–368]	15.0	[0–279]	0.09
CSF opening pressure (cm CSF, n=339)	37	[20–60]	36	[20–75]	0.85
Recent weight gain present (self-reported), n=396)	68	[26.6%]	44	[27.8%]	0.77
Treatment
Medication**	239	[93.4%]	145	[91.8%]	0.54
Diet Modification	102	[39.8%]	71	[44.9%]	0.31
Number of lumbar punctures	1	[1–18]	1	[1–20]	0.30
CSF Shunt	65	[25.4%]	30	[19%]	0.13
Optic nerve sheath fenestration					0.41
Unilateral	15	[5.9%]	11	[7%]
Bilateral	7	[2.7%]	8	[5.1%]

BMI (body mass index), y (years), CSF (cerebrospinal fluid), wk (weeks)

^*Contributing medications include vitamin A preparations, minocycline, doxycycline, tetracycline, depot progestins, oral contraceptives, cyclosporine, tacrolimus and recent discontinuation of steroids.

^**With acetazolamide, furosemide or topiramate